» Articles » PMID: 21805646

Synthesis and Antitumor Molecular Mechanism of Agents Based on Amino 2-(3',4',5'-trimethoxybenzoyl)benzo[b]furan: Inhibition of Tubulin and Induction of Apoptosis

Abstract

Induction of apoptosis is a promising strategy that could lead to the discovery of new molecules active in cancer chemotherapy. This property is generally observed when cells are treated with agents that target microtubules, dynamic structures that play a crucial role in cell division. Small molecules such as benzo[b]furans are attractive as inhibitors of tubulin polymerization. A new class of inhibitors of tubulin polymerization based on the 2-(3',4',5'-trimethoxybenzoyl)benzo[b]furan molecular skeleton, with the amino group placed at different positions on the benzene ring, were synthesized and evaluated for antiproliferative activity, inhibition of tubulin polymerization, and cell-cycle effects. The methoxy substitution pattern on the benzene portion of the benzo[b]furan moiety played an important role in affecting antiproliferative activity. In the series of 5-amino derivatives, the greatest inhibition of cell growth occurred if the methoxy substituent is placed at the C6 position, whereas C7 substitution decreases potency. The most promising compound in this series is 2-(3',4',5'-trimethoxybenzoyl)-3-methyl-5-amino-6-methoxybenzo[b]furan (3 h), which inhibits cancer cell growth at nanomolar concentrations (IC(50) =16-24 nM), and interacts strongly with tubulin by binding to the colchicine site. Sub-G(1) apoptotic cells in cultures of HL-60 and U937 cells were observed by flow cytometric analysis after treatment with 3 h in a concentration-dependent manner. We also show that compound 3 h induces apoptosis by activation of caspase-3, -8, and -9, and this is associated with cytochrome c release from mitochondria. The introduction of an α-bromoacryloyl group increased antiproliferative activity with respect to the parent amino derivatives.

Citing Articles

Synthesis and Biological Evaluation of Novel 2-Aroyl Benzofuran-Based Hydroxamic Acids as Antimicrotubule Agents.

Mariotto E, Canton M, Marchioro C, Brancale A, Hamel E, Varani K Int J Mol Sci. 2024; 25(14).

PMID: 39062759 PMC: 11277476. DOI: 10.3390/ijms25147519.


Synthesis and Biological Studies of Benzo[]furan Derivatives: A Review from 2011 to 2022.

Arce-Ramos L, Castillo J, Becerra D Pharmaceuticals (Basel). 2023; 16(9).

PMID: 37765074 PMC: 10537293. DOI: 10.3390/ph16091265.


Novel iodoacetamido benzoheterocyclic derivatives with potent antileukemic activity are inhibitors of STAT5 phosphorylation.

Romagnoli R, Baraldi P, Prencipe F, Lopez-Cara C, Rondanin R, Simoni D Eur J Med Chem. 2015; 108:39-52.

PMID: 26629859 PMC: 4724257. DOI: 10.1016/j.ejmech.2015.11.022.


Design, synthesis, in vitro, and in vivo anticancer and antiangiogenic activity of novel 3-arylaminobenzofuran derivatives targeting the colchicine site on tubulin.

Romagnoli R, Baraldi P, Salvador M, Prencipe F, Lopez-Cara C, Schiaffino Ortega S J Med Chem. 2015; 58(7):3209-22.

PMID: 25785605 PMC: 4407803. DOI: 10.1021/acs.jmedchem.5b00155.


VDAC1: from structure to cancer therapy.

Shoshan-Barmatz V, Mizrachi D Front Oncol. 2012; 2:164.

PMID: 23233904 PMC: 3516065. DOI: 10.3389/fonc.2012.00164.

References
1.
Hori K, Saito S . Microvascular mechanisms by which the combretastatin A-4 derivative AC7700 (AVE8062) induces tumour blood flow stasis. Br J Cancer. 2003; 89(7):1334-44. PMC: 2394288. DOI: 10.1038/sj.bjc.6601261. View

2.
Soldani C, Scovassi A . Poly(ADP-ribose) polymerase-1 cleavage during apoptosis: an update. Apoptosis. 2002; 7(4):321-8. DOI: 10.1023/a:1016119328968. View

3.
Verdier-Pinard P, Lai J, Yoo H, Yu J, Marquez B, Nagle D . Structure-activity analysis of the interaction of curacin A, the potent colchicine site antimitotic agent, with tubulin and effects of analogs on the growth of MCF-7 breast cancer cells. Mol Pharmacol. 1998; 53(1):62-76. DOI: 10.1124/mol.53.1.62. View

4.
Vincent L, Kermani P, Young L, Cheng J, Zhang F, Shido K . Combretastatin A4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular endothelial-cadherin signaling. J Clin Invest. 2005; 115(11):2992-3006. PMC: 1253622. DOI: 10.1172/JCI24586. View

5.
Chaudhary A, Pandeya S, Kumar P, Sharma P, Gupta S, Soni N . Combretastatin a-4 analogs as anticancer agents. Mini Rev Med Chem. 2008; 7(12):1186-205. DOI: 10.2174/138955707782795647. View